Both CK5 and CK6 expressions were linked to high grade, estrogen and progesterone receptor negativity, and “triple negativity” in breast cancer (p < 0.0001 each), grade/stage progression in urothelial cancer (p < 0.0001), and RAS mutations in colorectal cancer (p < 0.01). This evidence concerns the gene PGR and breast carcinoma.